The Role of IgM-Enriched Immunoglobulin (Pentaglobin) in Septic Patients with Hematological Disease

Pedro Amoedo Fernandes; Flavia Tobaldini Russo; Lucas Augusto  Monetta da Silva; Lafayete Willian  Ferreira Ramos; Aline de  Almeida Simões; Larissa Yukari Okada; Jamilla Neves Cavalcante; Maricy Almeida Viol  Ferreira Lopes; Maria Cristina Martins  de Almeida Macedo; Roberto Luiz  da Silva

doi:10.18502/ijhoscr.v15i2.6041

Pedro Amoedo Fernandes Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil
Flavia Tobaldini Russo Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil
Lucas Augusto Monetta da Silva Faculdade de Ciências Médicas Santa Casa de São Paulo, São Paulo, SP, Brasil
Lafayete Willian Ferreira Ramos Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil
Aline de Almeida Simões Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil
Larissa Yukari Okada Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil
Jamilla Neves Cavalcante Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil
Maricy Almeida Viol Ferreira Lopes Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil
Maria Cristina Martins de Almeida Macedo Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil
Roberto Luiz da Silva Instituto Brasileiro de Controle do Câncer (IBCC), São Paulo, SP, Brasil

DOI: https://doi.org/10.18502/ijhoscr.v15i2.6041

Keywords: Pentaglobin; Sepsis; Hematological disease

Abstract

Background: Patients with hematological disease are 15 times more likely to develop sepsis than the general population. The patient with hematological disease and, mainly, those undergoing hematopoietic stem cell transplantation (HSCT), develop a severe secondary humoral immunodeficiency, with low serum levels of IgM, which may take more than a year to be restored.

Materials and Methods: This is a retrospective, controlled and observational study that analyzed 51 patients with underlying hematological disease, who were diagnosed with sepsis or septic shock during the study period, to evaluate whether IgM-rich Ig replacement decreases the 30-day mortality.

Results: Of the 51 patients, 35 patients received IgM-rich immunoglobulin (group A) and 16 (31%) received conventional therapy. Eleven (69%) patients in the control group were alive after 30 days compared to 11 (34%) patients in the intervention group, p= 0.013.

Conclusion: There are no apparent benefits in the use of IgM-rich immunoglobulin in septic patients with hematological disease.